Neurological Aspects of Taste Disorders

Heckmann, Josef G.; Heckmann, Siegfried M.; Läng, Christoph; Hummel, Thomas

doi:10.1001/archneur.60.5.667

Cited by 101 publications

(97 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensory analysis O sabor é considerado como uma experiência mista, mas unitária de sensações olfativas, gustativas e táteis percebidas durante a degustação. É baseado na detecção de produtos químicos por células especializadas, sendo percebido, principalmente, através dos sentidos do gosto e olfato, também inuenciado pelos efeitos táteis, térmicos e dolorosos (HECKMANN, 2003;IAL, 2005;DUTCOSKY, 2007).…”

Section: Introductionunclassified

Percepção De Sabor: Uma Revisão

Strapasson

López

Basso

et al. 2011

View full text Add to dashboard Cite

A percepção de sabor é fator importante relacionado à qualidade de vida dos indivíduos. Distúrbios dessa percepção podem levar ao consumo de substâncias tóxicas ou ao consumo exagerado de substâncias que podem interferir no tratamento de doenças, como sal na hipertensão e açúcar no diabetes. Esta percepção ocorre pela união dos sentidos químicos (gosto e olfato) com as sensações táteis. As principais responsáveis são as papilas gustativas, presentes nos órgãos de entrada no sistema digestório. Esta sensação é variável de acordo com o estado psicológico e cultural do indivíduo e tem grande importância no desenvolvimento e determinação da qualidade de produtos alimentícios. Esse artigo busca reunir conhecimentos atuais sobre a percepção de sabor e limiar de percepção.

show abstract

Section: Introductionunclassified

Percepção De Sabor: Uma Revisão

Strapasson

López

Basso

et al. 2011

View full text Add to dashboard Cite

show abstract

“…To report dysgeusia as neuropathy, the cranial nerves (VII, IX, X) must be documented, as gustatory information from the taste buds is carried by specific branches of three, not only one, cranial nerves [8]. Grade 1-2 toxicities are reported in many clinical trials in a summative way, carrying the risk of underreporting the "true burden" of taste alterations [12].…”

Section: Introductionmentioning

confidence: 99%

“…Taste alterations are also associated with stomatitis [15], zinc deficiency [8], and antineoplastic agents other than taxanes, specifically cisplatin and doxorubicin [12]. Taste alterations are also frequent (60%) in far-advanced cancer patients without anticancer treatment [16].…”

Section: Introductionmentioning

confidence: 99%

Prevention of Docetaxel- or Paclitaxel-Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo-Controlled, Double-Blind Study

et al. 2008

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the frequency, clinical presentation, and patient burden of taste alterations and peripheral neuropathy in patients receiving taxane-based chemotherapy.2. Identify the risk factors for developing peripheral neuropathy and taste alterations associated with taxanes.3. Administer glutamine treatment in the supportive care of peripheral neuropathy and taste alterations and evaluate emerging new agents.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTTaste alteration (dysgeusia), an underrecognized toxicity associated with taxane-based chemotherapy (TaxCh), lacks standard treatment. We investigated prevention of dysgeusia with oral glutamine in patients undergoing first-time TaxCh. Adult patients were randomized to receive either 30 g/day glutamine or placebo (maltodextrin) from day 1 of TaxCh. Dysgeusia was measured daily with a visual analogue scale (VAS). On each chemotherapy cycle, objective (sour, sweet, salty, bitter) and subjective (fourcategory scale) taste and toxicity (National Cancer Institute Common Toxicity Criteria, v.3) were assessed. Stomatitis and zinc deficiency were treated. For primary outcomes, repeated dysgeusia scores were analyzed with a linear mixed model. Repeated data on each objective or subjective taste item were analyzed with a generalized estimating equation.Of 52 patients randomized, 41 completed treatment (median study duration, 74 days). At baseline, the glutamine (n ‫؍‬ 21) and placebo (n ‫؍‬ 20) groups were comparable for age (64 years), gender (32% men), tumor types, chemotherapy (docetaxel, 44%; paclitaxel, 56%), schedule (weekly, 78%; 3-weekly, 22%), treatment intention (15% adjuvant), dysgeusia (VAS, 11/100), and taste recognition (88%). Twenty-four patients had peripheral neuropathy grades 1-2; none had grade 3. Glutamine and placebo were not different for maximal dysgeusia and increase from baseline, with an insignificant linear time effect. Separate subgroup analyses for patients with baseline dysgeusia <11 or >11 did not alter the results. Objective or subjective taste tests were not different, neither were adverse events.Compared with placebo, oral glutamine did not prevent or decrease subjective taste disturbances or altered taste perception associated with TaxCh. The role of glutamine in supportive care of taxane-associated dysgeusia seems limited. The Oncologist 2008;13: 337-346

show abstract

“…The gustatory afferent nerves end in the nucleus of the solitary tract of the medulla from which the information runs to the thalamus and then to the cortex. Analogous to the olfactory pathway, taste information also connects to the amygdala and hippocampus (20). Results from functional MR imaging indicate that cortical areas including the insula and orbitofrontal cortex also are involved in the processing of gustatory stimuli (21,22).…”

Section: Discussionmentioning

confidence: 99%

Frequency and Characteristics of Taste Impairment in Patients with Parkinson's Disease: Results of a Clinical Interview

2011

View full text Add to dashboard Cite

Objective Patients with Parkinson's disease (PD) frequently complain of a diminished sense of smell. Less frequently, they may complain of taste impairment. In the present study, we investigated the symptoms, frequency, and severity of taste impairment as well as smell impairment in PD patients and compared the results with those of age-and sex-matched healthy controls. Patients and MethodsWe interviewed 285 PD patients (120 men, 165 women) without dementia or nasal problems. Control subjects comprised 61 (20 men, 41 women) healthy spouses of the PD patients. Alteration of smell and taste sense lasting more than 3 months was defined as abnormal. Results One hundred and sixteen patients with PD complained of smell impairment and 26 complained of taste impairment. Only 5 controls complained of smell impairment, and no control subjects reported taste impairment. Taste impairment was more marked in patients with smell impairment. Impaired taste included diminished taste perception in 21 patients, altered sense of taste in 4 patients and burning mouth in 1 patient. Conclusion Taste as well as smell perception is impaired in patients with PD. The frequency of smell and taste impairments tended to increase with disease progression.

show abstract

Neurological Aspects of Taste Disorders

Cited by 101 publications

References 43 publications

Percepção De Sabor: Uma Revisão

Percepção De Sabor: Uma Revisão

Prevention of Docetaxel- or Paclitaxel-Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo-Controlled, Double-Blind Study

Frequency and Characteristics of Taste Impairment in Patients with Parkinson's Disease: Results of a Clinical Interview

Contact Info

Product

Resources

About